Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

IJPPE > IJPPE Volume 4 > An Evaluation of the Relative Distribution of...
< Back to Volume

An Evaluation of the Relative Distribution of Romanian Patients with Pancreatic Neoplasm

Full Text PDF


This study describes the specific features of the distribution of Romanian patients with pancreatic neoplasm. The analysis was made on 188 patients from Clinical Emergency Hospital “Sf. Spiridon, Iasi”, Romania, all with solid form of pancreatic cancer. Moreover, the distribution by age, gender, tumor location in the pancreas or by the stages from the TNM system was analyzed and compared with other studies from other countries. Thus, in our sample the median age was 65 years old. In addition, 53% of the patients had rural origin and 47% urban origin. Also, regarding the pancreatic tumor location, by far the most frequent was the cephalic location (75%). Moreover, when we study the distribution by presence of metastases at the time of diagnosis, we observed that 62.1% are located in the liver and 21.2% into the peritoneum. In addition, when we staged the ductal adenocarcinoma of the pancreas according to the TNM (tumour grade, nodal status and metastases) system, where T1-T3 constitutes a resectable tumour and T4 indicates an unresectable tumour, we found that group T4 stage tumor predominated (63.8%), while in regards to the regional lymph nodes (e.g. N in TNM classification) we observed that in an overwhelming proportion Nx stage predominates (88.6%). Moreover, no distant metastasis was found in 63% of patients, by using M in TNM classification. In this way, a better understanding of the specific characteristics for the affected population could prove to be extremely important, especially considering the fact during the last decades the development of the surgical methods and techniques for this disorder had no significant impact on the survival rate.


International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 4)
D. Timofte et al., "An Evaluation of the Relative Distribution of Romanian Patients with Pancreatic Neoplasm", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 4, pp. 83-89, 2016
Online since:
August 2016

[1] H. Beger, Treatment of pancreatic cancer: challenge of the facts, World J Surg. 27 (2003) 1075-1084.

[2] V. Surlin et al., Prognostic factors in resectable pancreatic cancer, Rev. Med. Chir. Soc. Med. Nat. Iasi. 118 (2014) 924-931.

[3] R. Pezzilli, Screening tests for pancreatic cancer: searching for the early symptoms or the population at risk, Jop. 5 (2004) 240-242.

[4] E. Tamm, Diagnosis, staging, and surveillance of pancreatic cancer, AJR Am J Roentgenol. 180 (2003) 1311-1323.

[5] D. Timofte et al., Molecular factors with predictive value for the survival rate in pancreatic cancer: focusing on CA 19-9, Analele Ştiinţifice ale Universităţii Alexandru Ioan Cuza, Secţiunea Genetică şi Biologie Moleculară. 15 (2014) 21-26.

[6] D. Timofte et al., The relevance of some tumoral markers in patients with pancreatic cancer, Analele Ştiinţifice ale Universităţii Alexandru Ioan Cuza, Secţiunea Genetică şi Biologie Moleculară, 15 (2014) 51-58.

[7] D. Timofte et al., The relevance of some molecular markers in recurrent pancreatic cancer: focusing on CA 19-9 and cytokeratins, Rev. Med. Chir. Soc. Med. Nat. Iasi. 119 (2015) 730-737.

[8] D. Timofte et al., Studying the Post-Operatory and Molecular Modifications in the Chronic Pancreatitis and Pancreatic Cancer - The Importance of the Micronutrients and Pancreatic Enzyme Supplementation, International Letters of Natural Sciences. 47 (2015).


[9] D. Timofte, L. Ionescu, L. Ochiuz, Mini-Review on the Glucose Metabolism Modifications after Pancreatic Resection, International Letters of Natural Sciences. 53 (2016) 65-71.


[11] National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, (2015).

[12] American Joint Committee on Cancer (AJCC) TNM staging system. American Cancer Society, (2013).

[13] S. Edge, D. Byrd, C. Compton CC, AJCC Cancer Staging Manual (ed 7th). New York: Springer; (2010).

[14] K. Bilimoria, D. Bentrem, C. Ko CY, Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database, Cancer. 110 (2007) 738-744.


[15] D. Michaud, Epidemiology of pancreatic cancer, Minerva Chir. 59 (2004) 99-111.

[16] M. Edderkaoui, E. Thrower, Smoking induced pancreatitis and pancreatic cancer, Pancreapedia: Exocrine Pancreas Knowledge Base, (2015).


[17] D. Yadav, A. Lowenfels, The Epidemiology of Pancreatitis and Pancreatic Cancer. Gastroenterology. 144 (2013) 1252-1261.


[18] L. Wang, G. Yang, X. Lu, Z. Huang, H. Li, Pancreatic cancer mortality in China, World J Gastroenterol. 9 (2003) 1819–1823.

[19] S. Sener, Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database, J. Am Coll. Surg. 189 (1999) 1-7.

[20] M. Del Chiaro, S. Presciuttini, L. Bertacca, A. Zerbi A, Clinical Pancreatic Cancer. HPB (Oxford). 7 (2005) 76–90.

[21] F. Greene, L. Sobin, The staging of cancer: a retrospective and prospective appraisal, CA Cancer J Clin. 58 (2008) 180–190.


[22] W. Nabil, Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging? Annals of Surgical Oncology. 17 (2010): 2312–2320.


[23] S. Chakraborty, S. Singh, Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study, Ann Gastroenterol. 26 (2013) 346–352.

[24] S. Yamada, T. Fujii, H. Sugimoto H, Pancreatic cancer with distant metastases: a contraindication for radical surgery? Hepatogastroenterology. 56 (2009) 881-885.

Show More Hide
Cited By:
This article has no citations.